AEE-788

Research use only, not for human use.

A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.

A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively; inhibits growth factor-induced EGFR and ErbB2 phosphorylation in cells with IC50 of 11 and 220 nM, respectively, demonstrates antiproliferative activity against a range of EGFR and ErbB2-overexpressing cell lines; shows antitumor and antiangiogenic activity in vivo.Brain Cancer Phase 2 Discontinued

AEE 788;AEE788;NVP-AEE 788

Angiogenesis

EGFR

c-Abl;c-Fms;EGFR;FLT1;HER2/ErbB2

Cancer

Brain Cancer

497839-62-0

440.58

C27H32N6

>98% (HPLC)

DMSO: 10 mM

C[C@@H](NC1=C2C(NC(C3=CC=C(CN4CCN(CC)CC4)C=C3)=C2)=NC=N1)C5=CC=CC=C5

7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 6-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-

(-20℃)

With Ice Pack

≥ 2 years